関連する実験動画
Updated: Sep 9, 2025
08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
16.1K
FASN/アルギナゼ/eNOS解離の組み合わせによる肥満および関連する心血管合併症の相乗効果的緩和
Ebtesam Ahmed Sabry1, Mahmoud H Elbatreek2, Hany M El-Basossy1
1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|August 29, 2025
まとめ
脂肪酸合成酵素/アルギナーゼ/内皮酸化窒素合成酵素 (FASN/ARG/eNOS) ネットワークをターゲットにすることで 肥満に対する新しい戦略が生まれます この軸を標的とした併用療法により,肥満ラットの代謝,心血管,炎症マーカーが相乗的に改善されました.
科学分野:
- システム医学
- 肥満に関する研究
- 心血管の合併症
背景:
- 肥満は世界的な健康危機であり 新しい治療戦略が必要です
- システム医学は病気のメカニズムを理解し,多目的の介入を設計するための枠組みを提供します.
- FASN/ARG/eNOSネットワークの調節不良は 肥満とその後遺症に関与しています
研究 の 目的:
- 肥満に関連した心臓血管合併症の標的治療法を調査する.
- FASN/ARG/eNOSネットワークを対象にメカニズムに基づく介入の有効性を評価する.
主な方法:
- 肥満はフルクトーゼと塩分を多く含んだ食物を摂取したラットで誘発された.
- ネズミはランダムにコントロール,肥満,および4つの治療グループに分けられました.
- 治療にはオルリスタット (FASN阻害剤),ノルヴァリン (ARG阻害剤),シトルリン/葉酸 (eNOS再結合),またはそれらの組み合わせが含まれていた.
主要な成果:
- 個々の治療は,脂肪,血圧,血糖制御,および血管機能の改善を示した.
- 統合された介入は,脂肪を大幅に減らし,代謝パラメータを改善して,相乗効果を示した.
- 併用療法により,心臓の改造,血圧の正常化,酸化ストレスおよび炎症に対する強力な保護が提供されました.
結論:
- 同時にFASN/ARG/eNOS軸をターゲットにすることは 肥満に対する有望な治療戦略です
- このネットワークをターゲットにしたメカニズムベースの治療法では 肥満とその心血管疾患の影響を 総合的に軽減することができます
関連する概念動画
01:26Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:24Obesity
609
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
609
01:29Heart Failure II: Pathophysiology
37
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
37
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K